ClinVar

Description

This variant is denoted PALB2 c.3047T>C at the cDNA level, p.Phe1016Ser (F1016S) at the protein level, and results in the change of a Phenylalanine to a Serine (TTT>TCT). This variant has been observed in at least one individual with a personal history of early-onset breast cancer and a family history of breast, ovarian, and pancreatic cancer (Vietri 2015). PALB2 Phe1016Ser was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Phenylalanine and Serine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. PALB2 Phe1016Ser occurs at a position that is conserved in mammals and is located within the region required for POLH DNA synthesis stimulation, the regions required for interaction with RAD51, BRCA2, and POLH, and within the WD-4 repeat (UniProt). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available evidence, it is unclear whether PALB2 Phe1016Ser is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.